What is comingChronic myeloid leukaemia (CML)

Drugs in phase 3 · 1

Trials under way · 14

• A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies · phase 1/2 · Ossium Health, Inc.
• A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) · phase 1/2 · Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
• A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs · phase 3 · Il-Yang Pharm. Co., Ltd.
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · phase 3 · Novartis Pharmaceuticals
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) · phase 3 · Novartis Pharmaceuticals
• Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia · phase 2 · Novartis Pharmaceuticals
• Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. · phase 2 · Novartis Pharmaceuticals
• Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) · phase 3 · Il-Yang Pharm. Co., Ltd.
• Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors · phase 1/2 · Incyte Biosciences International Sàrl
• Study of Olverembatinib (HQP1351) in Patients With CML-CP · phase 3 · Ascentage Pharma Group Inc.
• Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia · phase 1/2 · Novartis Pharmaceuticals
• Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP · phase 2 · Novartis Pharmaceuticals
• TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients · phase 2 · Shenzhen TargetRx Co., Ltd.
• The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation · phase 2 · Otsuka Beijing Research Institute

Trials reported · 3

• DASISION · phase 3 · 2010 · positive
• Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients · phase 2 · 2011 · completed
• Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients · phase 2 · completed